Since joining Kirkland, Adam has been involved in the following representations:
- Amicus Therapeutics in its $4.8 billion sale to BioMarin
- Akero Therapeutics in its sale to Novo Nordisk for up to $5.2 billion
- Sage Therapeutics in its $795 million sale to Supernus Pharmaceuticals
Prior to joining Kirkland, Adam was involved in the following representations:
- The special committee of AspenTech in its subsequent $7.2 billion sale to Emerson Electric of all shares of AspenTech not already owned by Emerson
- The special committee of the board of directors of R1 RCM in its sale to investment funds affiliated with TowerBrook Capital Partners and Clayton Dubilier & Rice for an enterprise value of $8.9 billion
- MorphoSys AG in its $2.9 billion sale to Novartis and simultaneous disposition of Monjuvi to Incyte
- Mirati Therapeutics in its sale to Bristol Myers Squibb for up to $5.8 billion
- Intercept Pharmaceuticals in its sale to Alfasigma for approximately $800 million
- Iveric Bio in its $5.9 billion sale to Astellas
